» Articles » PMID: 39345531

Common Regulatory Mutation Increases Single-cell Survival to Antibiotic Exposures in

Overview
Journal bioRxiv
Date 2024 Sep 30
PMID 39345531
Authors
Affiliations
Soon will be listed here.
Abstract

Typical antibiotic susceptibility testing (AST) of microbial samples is performed in homogeneous cultures in steady environments, which does not account for the highly heterogeneous and dynamic nature of antibiotic responses. The most common mutation found in lineages evolved in the human lung, a loss of function of repressor MexZ, increases basal levels of multidrug efflux MexXY, but does not increase resistance by traditional MIC measures. Here, we use single cell microfluidics to show that response to aminoglycosides is highly heterogeneous, with only a subpopulation of cells surviving exposure. mutations then bypass the lengthy process of MexXY activation, increasing survival to sudden drug exposures and conferring a fitness advantage in fluctuating environments. We propose a simple "Response Dynamics" assay to quantify the speed of population-level recovery to drug exposures. This assay can be used alongside MIC for resistance profiling to better predict clinical outcomes.

References
1.
Abed W, Mohammed Kareem S . Molecular detection of gyrA and mexA genes in Pseudomonas aeruginosa. Mol Biol Rep. 2021; 48(12):7907-7912. DOI: 10.1007/s11033-021-06820-0. View

2.
Vogne C, Aires J, Bailly C, Hocquet D, Plesiat P . Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2004; 48(5):1676-80. PMC: 400545. DOI: 10.1128/AAC.48.5.1676-1680.2004. View

3.
Marvig R, Sommer L, Molin S, Krogh Johansen H . Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet. 2014; 47(1):57-64. DOI: 10.1038/ng.3148. View

4.
Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet D . Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008; 52(3):1173-5. PMC: 2258510. DOI: 10.1128/AAC.01212-07. View

5.
Morita Y, Tomida J, Kawamura Y . MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol. 2012; 3:408. PMC: 3516279. DOI: 10.3389/fmicb.2012.00408. View